Price
$143.34-9.44%Social Signal Score
Analyst Ratings
50 analysts52-week range
- Last close
- $143.34
- Off 52w high
- -59.4%
- 200-day average
- $223.41
- vs 200-day
- -35.8%
Revenue
$801.70M+745.04%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ashley McEvoy
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 5,400
- Beta
- 1.08
- Country
- US
- Piotroski score
- 9 / 9 (Strong)
- Altman Z-score
- 5.32
Financials
Revenue
$801.70M+745.0%Net Income
$95.00MEBITDA
$132.20M+3466.2%Free Cash Flow
$59.40MEPS (diluted)
$1.37Shares Outstanding (diluted)
69.40M+21.0%Operating Expenses
$432.90MCash & Debt
$534.90MReturn of Capital
$0.00Revenue by Segment (annual)
$2.71BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.71B | $247.10M | $3.51 |
| 2024 | $2.07B | $418.30M | $5.97 |
| 2023 | $1.70B | $206.30M | $2.96 |
| 2022 | $1.31B | $4.60M | $0.07 |
| 2021 | $1.10B | $16.80M | $0.25 |
| 2020 | $904.40M | $6.80M | $0.11 |
| 2019 | $738.20M | $11.60M | $0.19 |
| 2018 | $563.82M | $3.29M | $0.06 |
| 2017 | $463.77M | $-26.83M | $-0.46 |
| 2016 | $366.99M | $-28.88M | $-0.51 |
| 2015 | $263.89M | $-73.52M | $-1.29 |
| 2014 | $288.72M | $-51.50M | $-0.93 |
| 2013 | $247.08M | $-44.97M | $-0.83 |
| 2012 | $211.37M | $-51.87M | $-1.08 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $5.16
- Implied price
- $92.90
- Return from $131.69
- -6.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $46.19 — -64.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -22.0% | -18.4% | -15.4% | -12.7% | -10.4% |
| 3.0% | -18.0% | -14.2% | -11.1% | -8.3% | -5.8% |
| 8.0% | -14.0% | -10.1% | -6.7% | -3.8% | -1.2% |
| 13.0% | -10.0% | -5.9% | -2.4% | 0.6% | 3.4% |
| 18.0% | -6.0% | -1.8% | 1.9% | 5.1% | 7.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-64.29%Social Signal Score
Mentions (23)
- News (RSS)investing·7d ago·Neutral
Why is Insulet stock sliding today?
View source ↗ - Newszacks.com·10d ago·Positive
Why Insulet (PODD) is a Top Growth Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newsmarketbeat.com·11d ago·Neutral
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum Insulet NASDAQ: PODD Chief Operating Officer Eric Benjamin said the company remains focused on expanding adoption of automated insulin delivery, or AID, systems across large and underpenetrated diabetes markets, while addressing elevated early attrition among certain Type 2 diabetes customers.
View source ↗ - News (RSS)seekingalpha·11d ago·Positive
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
View source ↗ - Newsseekingalpha.com·11d ago·Positive
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
View source ↗ - Newsbusinesswire.com·18d ago·Positive
…let to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum on Thursday, September 24, 2026, at 12:30 p.m. (Eastern Time). The live webcast and replay of the presen…
View source ↗ - News (RSS)seekingalpha·26d ago·Positive
Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newszacks.com·26d ago·Positive
Here's Why Insulet (PODD) is a Strong Growth Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newszacks.com·31d ago·Neutral
Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report? Insulet (PODD) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsbusinesswire.com·36d ago·Negative
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $PODD--PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with SBS Law.
View source ↗ - Newsgurufocus.com·36d ago·Neutral
Insulet Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PODD Insulet Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PODD PR Newswire
View source ↗ - News (RSS)seekingalpha·37d ago·Positive
Insulet Corporation: Strong Growth Meets A New Execution Problem
View source ↗ - News (RSS)yahoo·41d ago·Neutral
Is Wall Street Bullish or Bearish on Insulet Stock?
View source ↗ - Newszacks.com·41d ago·Positive
Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat? Insulet's Q2 beat and stronger margins contrast with a 2026 growth reset, putting U.S. Type 2 retention at the center of its outlook.
View source ↗ - Newsprnewswire.com·42d ago·Negative
Insulet Corporation (PODD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit BENSALEM, Pa., Aug. 24, 2026 /PRNewswire/ -- The Law Offices of Howard G.
View source ↗ - 4chan /biz/biz·47d ago·Neutral
>>62609547 >Long term shorts LULU, YETI, TRUP, COTY, BBWI, RUN, PODD Shorting the Becky Index, very spicy anon
View source ↗ - News (RSS)yahoo·53d ago·Neutral
Insulet Corporation’s (PODD) Wearable Pod Tech Finds New Frontier
View source ↗ - Newszacks.com·53d ago·Positive
Why Insulet (PODD) is a Top Growth Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - News (RSS)fool·54d ago·Positive
Insulet (PODD) Q2 2026 Earnings Call Transcript Type 2 retention challenges force management to trim full-year outlook despite revenue beat.
View source ↗ - Newsprnewswire.com·56d ago·Negative
Insulet Corporation (PODD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit BENSALEM, Pa., Aug. 10, 2026 /PRNewswire/ -- The Law Offices of Howard G.
View source ↗ - Newszacks.com·56d ago·Positive
PODD's Q2 Earnings Top Estimates, FY'26 Sales View Cut, Stock Down Insulet's Q2 results beat estimates on strong Omnipod demand and wider margins, but its 2026 revenue outlook takes a hit.
View source ↗ - Newsgurufocus.com·57d ago·Neutral
Insulet Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PODD Insulet Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PODD PR Newswire
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $1.59 per share
Typical surprise +15.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$1.66 vs $1.47beat
- Wed, May 6$1.42 vs $1.19beat
- Wed, Feb 18$1.55 vs $1.47beat
- Thu, Nov 6$1.24 vs $1.14beat
- Thu, Aug 7$1.17 vs $0.92beat
- Thu, May 8$1.02 vs $0.79beat
Estimates and results for PODD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PODD officers and directors.
- Bought
- $2.4m
- Sold
- $4.2m
5 trades
9 trades
- Mcevoy Ashleybought
- Stonesifer Timothy C.bought
- Borio Lucianasold
- Minogue Michael Rbought
- Mcevoy Ashleybought
- Frederick Wayne A.i.sold
- Stonesifer Timothy C.bought
- Singh Premsold
86 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Sep 11, 2026 (24d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 11, 2026 (41d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (39d later)Buy$1,001 - $15,000
- Markwayne Mullinsenate · OK · disclosed Aug 12, 2025 (599d later)Sell$1,001 - $15,000
- Markwayne Mullinsenate · OK · disclosed Aug 12, 2025 (586d later)Sell$1,001 - $15,000
- Markwayne Mullinsenate · OK · disclosed Jul 30, 2025 (939d later)Buy$1,001 - $15,000
- Tina Smithsenate · MN · disclosed Apr 19, 2024 (15d later)Sell$50,001 - $100,000
- Markwayne Mullinsenate · OK · disclosed Jan 26, 2024 (35d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (33d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (37d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (8d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 6, 2023 (8d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (32d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 7, 2023 (10d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 11, 2023 (15d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (20d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed May 19, 2023 (39d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 10, 2022 (31d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 10, 2022 (18d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.